Monte Rosa Therapeutics (GLUE) News Today $5.16 -0.10 (-1.90%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$5.20 +0.04 (+0.68%) As of 07/11/2025 06:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GLUE Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Monte Rosa Announces Publication in Science of Key Insights that Enable Next Generation Molecular Glue Degrader MedicinesJuly 3, 2025 | globenewswire.comMonte Rosa Therapeutics Announces FDA Clearance of IND Application for MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory DiseasesJune 10, 2025 | globenewswire.comMonte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Shares Purchased by Two Sigma Investments LPJune 2, 2025 | marketbeat.comMonte Rosa Therapeutics to Participate in the Jefferies Global Healthcare ConferenceMay 28, 2025 | globenewswire.comVestal Point Capital LP Sells 505,000 Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)May 21, 2025 | marketbeat.comSuvretta Capital Management LLC Sells 1,095,202 Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)May 19, 2025 | marketbeat.comCubist Systematic Strategies LLC Makes New $644,000 Investment in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)May 18, 2025 | marketbeat.comParkwood LLC Sells 103,620 Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)May 16, 2025 | marketbeat.comAnalysts Set Expectations for GLUE Q4 EarningsMay 14, 2025 | marketbeat.comMonte Rosa Therapeutics Announces First Quarter 2025 Financial Results and Business UpdatesMay 8, 2025 | globenewswire.comBVF Inc. IL Invests $19.19 Million in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)May 6, 2025 | marketbeat.comMonte Rosa Therapeutics (GLUE) Expected to Announce Earnings on ThursdayMay 3, 2025 | marketbeat.comPrice T Rowe Associates Inc. MD Increases Holdings in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)May 2, 2025 | marketbeat.comMonte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2025 on the Potential of its CDK2-directed Molecular Glue Degrader to Treat HR-positive/HER2-negative Breast CancerApril 28, 2025 | globenewswire.comMonte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Shares Purchased by Marshall Wace LLPApril 28, 2025 | marketbeat.comAvoro Capital Advisors LLC Has $30.15 Million Holdings in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)April 23, 2025 | marketbeat.comJump Financial LLC Buys Shares of 154,842 Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)April 23, 2025 | marketbeat.comMonte Rosa Therapeutics Insider Ups Holding During YearApril 22, 2025 | finance.yahoo.comMonte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Short Interest Down 23.0% in MarchApril 21, 2025 | marketbeat.comVanguard Group Inc. Buys 622,134 Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)April 17, 2025 | marketbeat.comNorges Bank Takes Position in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)April 13, 2025 | marketbeat.comShort Interest in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Drops By 12.6%April 3, 2025 | marketbeat.comVersant Venture Management LLC Purchases New Stake in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)March 27, 2025 | marketbeat.comInsider Buying: Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Director Buys 10,000 Shares of StockMarch 26, 2025 | marketbeat.comMonte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Director Acquires $58,400.00 in StockMarch 26, 2025 | insidertrades.comMonte Rosa Therapeutics: Exercise Extreme CautionMarch 25, 2025 | seekingalpha.comFY2029 Earnings Estimate for GLUE Issued By WedbushMarch 24, 2025 | marketbeat.comMonte Rosa Therapeutics price target raised to $17 from $15 at WedbushMarch 23, 2025 | markets.businessinsider.comMonte Rosa Therapeutics price target lowered to $10 from $11 at Wells FargoMarch 22, 2025 | markets.businessinsider.comMonte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Q4 2024 Earnings Call TranscriptMarch 22, 2025 | msn.comMonte Rosa Therapeutics (NASDAQ:GLUE) Price Target Lowered to $10.00 at Wells Fargo & CompanyMarch 22, 2025 | marketbeat.comPiper Sandler Reaffirms Their Buy Rating on Monte Rosa Therapeutics (GLUE)March 22, 2025 | markets.businessinsider.comWedbush Sticks to Its Buy Rating for Monte Rosa Therapeutics (GLUE)March 22, 2025 | markets.businessinsider.comMonte Rosa Therapeutics Earnings Call Highlights Progress and Strategic ShiftsMarch 21, 2025 | tipranks.comMonte Rosa Therapeutics (NASDAQ:GLUE) Earns Outperform Rating from WedbushMarch 21, 2025 | marketbeat.comMonte Rosa Therapeutics (NASDAQ:GLUE) Posts Earnings Results, Beats Expectations By $0.50 EPSMarch 21, 2025 | marketbeat.comMonte Rosa Therapeutics reports Q4 revenue $60.6M, consensus $51.9MMarch 21, 2025 | markets.businessinsider.comMonte Rosa Therapeutics files $400M mixed securities shelfMarch 21, 2025 | markets.businessinsider.comMonte Rosa Therapeutics, Inc. (GLUE) Q4 2024 Earnings Call TranscriptMarch 21, 2025 | seekingalpha.comMixed data results for two Monte Rosa molecular glue degradersMarch 21, 2025 | finance.yahoo.comMonte Rosa Therapeutics shares surge on strong Q4 revenue beatMarch 20, 2025 | in.investing.comMonte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results from MRT-6160 and MRT-2359 ProgramsMarch 20, 2025 | globenewswire.comBrokers Offer Predictions for GLUE FY2024 EarningsMarch 15, 2025 | marketbeat.comLifeSci Capital Initiates Coverage of Monte Rosa Therapeutics (GLUE) with Outperform RecommendationMarch 13, 2025 | msn.comLifesci Capital Initiates Coverage on Monte Rosa Therapeutics (NASDAQ:GLUE)March 13, 2025 | marketbeat.comMonte Rosa Therapeutics initiated with an Outperform at LifeSci CapitalMarch 12, 2025 | markets.businessinsider.comAlphaQuest LLC Takes $657,000 Position in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)March 12, 2025 | marketbeat.comMonte Rosa Therapeutics to Present Pipeline Update and Release Fourth Quarter and Full Year 2024 Financial Results on March 20, 2025March 11, 2025 | globenewswire.comMonte Rosa Therapeutics (GLUE) Projected to Post Earnings on ThursdayMarch 6, 2025 | marketbeat.comMonte Rosa Therapeutics to Present at the TD Cowen 45th Annual Health Care ConferenceFebruary 24, 2025 | globenewswire.com Get Monte Rosa Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GLUE and its competitors with MarketBeat's FREE daily newsletter. Email Address GLUE Media Mentions By Week GLUE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GLUE News Sentiment▼1.871.00▲Average Medical News Sentiment GLUE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GLUE Articles This Week▼12▲GLUE Articles Average Week Get Monte Rosa Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GLUE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ABCL News PAHC News NTLA News WVE News COGT News CVAC News AUPH News CALT News HROW News ARDX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GLUE) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Monte Rosa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Monte Rosa Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
